ALSO NOTED: Akorn inks pact with Sofgen; new cancer start-up; and much more...

> Akorn and Sofgen Pharmaceuticals have inked a development and marketing pact for a new nausea drug. No financial terms were disclosed. Akorn said it expects to launch the drug in 2008. Report [1]

> Affiliates of the European Molecular Biology Laboratory have formed a start-up, Elara Pharmaceuticals GmbH, aimed at developing anti-cancer therapies. Report [2]

> BioDelivery Sciences International says that its Bioral gene delivery technology was used to administer a siRNA therapy, significantly reducing the load of bird virus in mice. That particular siRNA targets gene segments in the H5N1 virus. Report [3]

> Philippine drug regulators have granted Epeius Biotechnologies accelerated approval for the company's lead clinical product, Rexin-G for the treatment of all solid tumors. Release [4]

> BrainCells has in-licensed a clinical-stage compound from Mitsubishi Pharma that BCI will reposition and develop for the treatment of central nervous system diseases, including mood disorders. Release [5]

> Cytori Therapeutics plans to sell $16.8 million in stock. Report [6]

And Finally… Experts say that synthetic testosterone won't give athletes a sudden jolt, but will help build endurance and strength over time. Article [7]